



## 2007: A further year of strong growth: up 16%

(€ millions)	2007		2006		07/06 % change
		% sales		% sales	
Southern Europe (1)	31.99	74.3	27.97	74.7	14
Other EU countries (2)	9.66	22.4	8.22	22.0	17
Other markets	1.40	3.3	1.27	3.3	10
SLIT	34.55	80.3	28.75	76.8	20
SCIT	7.12	16.5	6.86	18.3	4
Other products	1.38	3.2	1.85	4.9	(25)
<b>Total Q4 sales</b>	<b>43.05</b>	<b>100.0</b>	<b>37.46</b>	<b>100.0</b>	<b>15</b>
Southern Europe (1)	109.15	74.2	93.68	74.0	17
Other EU countries (2)	32.49	22.1	28.00	22.1	16
Other markets	5.42	3.7	4.87	3.9	11
<b>FY sales</b>	<b>147.06</b>	<b>100.0</b>	<b>126.55</b>	<b>100.0</b>	<b>16</b>
SLIT	116.43	79.2	96.30	76.1	21
SCIT	24.90	16.9	24.09	19.0	3
Other products	5.73	3.9	6.16	4.9	(7)
<b>FY cumulated sales</b>	<b>147.06</b>	<b>100.0</b>	<b>126.55</b>	<b>100.0</b>	<b>16</b>

(1) Portugal, Spain, France, Italy, Greece; (2) including Switzerland

### Sales growth and financial position

2007 4<sup>th</sup> quarter sales registered a further 15% growth in all markets.

2007 full-year growth was 16%, driven by the strength of the sublingual route desensitisation segment (SLIT), which grew 21%. The significant increase in the number of new patients, in particular in France and Germany, and growing sales excluding subsidiaries were the main growth drivers.

2007 results, should exceed those of 2006 (EBIT of € 23 million), in spite of a further significant increase in R&D expenses.

### 2008 outlook

The Group gives guidance of double-digit sales growth. 2008 results should be impacted by additional R&D investments in the US.

The questions asked by the German agency regarding the ORALAIR<sup>®</sup> Grasses file have been dealt with and we expect a licence to be issued.

Talks are continuing with potential partners in the US.

## About STALLERGENES

STALLERGENES is a European biopharmaceutical company dedicated to desensitization treatments for the prevention and cure of allergy-related respiratory diseases, e.g. rhino-conjunctivitis, rhinitis and allergic asthma.

A pioneer and leader in sublingual desensitization treatments, STALLERGENES devotes 18% of its sales to Research and Development and is today fully involved in the development of a new therapeutic family, the sublingual desensitization tablets.

STALLERGENES realised 2007 sales of € 147 million, of which half outside France.

STALLERGENES' shares are listed on Compartment B of the Euronext Paris Stock Exchange.

ISIN code: FR0000065674, Reuters code: GEN.PA, Bloomberg code: GEN.FP

For additional information on STALLERGENES, please visit our website: [www.stallergenes.com](http://www.stallergenes.com)



---

### Your contacts

### PAVIE FINANCE

Albert SAPORTA - Chairman

Christian THIRY - Chief Financial Officer

Tel: +33 (0)1 55 59 20 95

[investorrelations@stallergenes.fr](mailto:investorrelations@stallergenes.fr)

Lucile de FRAGUIER

Analyst-investor Relations

Tel: +33 (0)1 42 15 04 39

[contact@pavie-finance.com](mailto:contact@pavie-finance.com)